A B S T R A C T A noncovalent complex of meningococcal group B polysaccharide and type 2 outer membrane protein has been characterized and its potential as a vaccine against group B meningococcal disease investigated. The polysaccharide component was found to have a partition coefficient, Kd, of 0.34 on Sepharose CL-4B in the presence of sodium deoxycholate. The protein consisted of four to five major proteins including the principal outer membrane protein. Hydrophobic binding between the protein and polysaccharide was demonstrated by gel filtration and isopycnic CsCl density gradient centrifugation and found to involve all of the proteins. After demonstrating safety and immunogenicity in animals, two lots of vaccine were tested in a total of eight volunteers. Two 120-,ug doses were given subcutaneously at 0 and 5 wk. Mild local reactions occurred in all eight volunteers, but no systemic reactions were observed. 2 wk after the first dose, six of the volunteers had increased levels of bactericidal antibodies against both the group B polysaccharide and the outer membrane proteins. Antibody rises to the group B polysaccharide (mean 6-fold) were confirmed by passive hemagglutination assays and rises to the proteins (mean 10-fold) by a solid phase radioimmunoassay. The second dose resulted in little or no increase in antibody titers. Antibody titers declined over a period of 14 wk but mostly remained above preimmunization levels. Bactericidal antibodies with specificity for the group B polysaccharide were mostly of the immunoglobulin (Ig)M class, and were directed against a determinant associated only with high molecular weight polysaccharides. We conclude that both the group B polysaccharide and the outer membrane protein are immunogenic in man when presented as a complex and that the complex warrants further testing and development as a vaccine against group B meningococcal disease.
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INTRODUCTION
Group B Neisseria meningitidis continues to be responsible for a major proportion of meningococcal disease in the United States (1), Europe (2) , and England (3) . Since the development of successful capsular polysaccharide vaccines for groups A and C in the late 1960s (4) , there has been a continuing effort in several laboratories to develop a suitable group B vaccine. Purified high molecular weight group B polysaccharide has been reported to lack substantial immunogenicity in man (5) . This result, together with evidence of poor antibody responses to the group B polysaccharide after natural group B infection (6, 7) , has led to the study of noncapsular surface antigens as potential vaccines (8) (9) (10) (11) . The serotype 2 outer membrane protein has been of particular interest because in recent years serotype 2 strains have been responsible for a high percentage of group B disease (3, 12, 13) , and the outer membrane proteins can be separated from the toxic lipopolysaccharide (LPS)1 in a form that is both immunogenic and protective in animals (8, 11) . Animal models, however, have thus far proven to be inadequate for predicting immunogenicity of meningococcal capsular polysaccharide (14) and outer membrane protein (8) antigens in human beings.
Because serum bactericidal activity has been correlated with immunity to meningococcal disease (15, 16) , our approach has been to identify the group B antigens against which human bactericidal antibodies are directed and to evaluate these antigens as potential vaccines. We have verified the presence ofbactericidal antibodies specific for the serotype proteins in convalescent phase human sera; and, in contrast to the findings of Wyle et al. (15) and Kasper et al. (17) , we have found that most adult human sera contain bactericidal antibodies specific for the group B polysaccharide (8) . 2 The latter result suggested that group B-specific bactericidal antibodies might be induced by vaccination if the antigen were properly presented. In a previous study, an experimental serotype 2 outer membrane protein vaccine prepared from a group C strain produced a cross-stimulation of bactericidal antibodies to the group B polysaccharide in a small number of volunteers (8) . These results suggested that outer membrane protein might function as an effective carrier for the group B capsular polysaccharide. Naturally occurring complexes of the capsular polysaccharide from Haemophilus influenzae and N. meningitidis with protein (presumably outer membrane protein) have been shown to exhibit increased immunogenicity in animals as compared with the purified polysaccharides (17, 18) . In addition, induction ofantibodies to both the group B polysaccharide and the serotype protein(s) may result in better protection than either specificity ofantibody alone (19) .
Ih the present report we show that both the group B polysaccharide and the type 2 outer membrane proteins are immunogenic in man when presented as a noncovalent complex. (20) and is expressed by the format (serogroup:protein serotype:LPS serotype). (Serotype P2 is the same as type 2 in the system of Frasch and Chapman [21] and Factor II in the system of Gold and Wyle [22] .) The group B strain 99M(B:P2,3,6:L3,7), which is also referred to as Bll, was used for production of the vaccines. The Escherichia coli strain 07:K1(L):NM was used for preparation of Kl capsular polysaccharide.
METHODS
Preparation of vaccines. Cultures were grown in 15-liter bottles as described (23) for 16 h at 36°C in the medium of Watson and Sherp (24) modified to contain 3% casamino acids (Certified, Difco Laboratories, Detroit, Mich.) and 0.1% glucose. Final pH after growth was 7.7-8.0.
Lot BP2-WZ-2 was prepared by combining partially purified group B polysaccharide from one culture with outer membrane complex (OMC) prepared from a second culture grown under the same conditions. The mixture was then processed further to remove LPS.
The partially purified group B polysaccharide was prepared by a modification of the method of Gotschlich et al. (14) . After addition of 0.1% hexadecyltrimethylammonium bromide to the culture, the precipitate was collected by continuous flow 2 16 ,000g for 10 min. The precipitate was washed twice with cold absolute ethanol and dissolved in cold distilled water. The solution was dialyzed overnight at 5°C against 10 vol distilled water and reprecipitated by addition of 1/10 vol of saturated sodium acetate followed by 2 vol of cold ethanol. The precipitate was collected by centrifugation at 16,000 g for 10 min and dissolved in distilled water. The sialic acid:protein ratio of this product was 1.6:1.
The OMC was prepared from 15 liters of culture after inactivation by 0.5% phenol for 2 h. The organisms (135 g wet wt) were collected by continuous flow centrifugation, suspended in 300 ml buffer containing 0.05 M Tris-chloride, 0.15 M NaCl, and 0.01 M EDTA, pH 7.4, and warmed at 56°C for 30 min. The suspension was then allowed to cool to room temperature, sheared in an Omnimixer (Dupont InstrumentsSorvall, DuPont Co., Newtown, Conn.) at full speed for 3 min, and centrifuged at 16,000 g for 15 min. The pellets were reextracted in the same way, and the supernates combined. The combined supernate was centrifuged first at 25,000 g for 15 min and then at 30,000 g for 20 min. The resulting supernate was centrifuged at 100,000 g for 2 h and the pelleted OMC suspended in about 300 ml of distilled water. The OMC was washed once by repelleting at 100,000 g for 2 h and suspended in 150 ml of distilled water. Enough of this suspension was combined with the partially purified capsular polysaccharide to make the sialic acid:protein ratio 1:1.2, and the resulting mixture was stored at -20°C in 60-ml portions.
LPS was removed by chromatography of each portion on Sephadex G-100 (Pharmacia Fine Chemicals, Piscataway, N. J.) in buffer containing 1% sodium deoxylcholate (DOC), 0.05 M glycine, and 0.005 M EDTA, pH 8.8. Each 60-ml sample was mixed with 30 ml of buffer concentrate containing 10% DOC, 0.15 M glycine, and 0.03 M EDTA, pH 8.8. The mixture was then warmed at 56°C for 30 min and centrifuged at 25,000 g for 10 min at 20°C. The pellets were discarded, and the supemate applied to the 5 x 90-cm column. The fractions (20 ml) comprising the void volume peak that contained the protein and sialic acid were pooled and kept at 5°C until all five samples had been chromatographed (4 
d).
The pooled fractions were warmed to 300C and prefiltered through a 0.45-,um membrane filter. The prefiltered material was then sterile filtered through a 0.2-,um membrane filter directly into 4 vol of cold, filter-sterilized ethanol. The resulting precipitate was collected by centrifugation at 16,000 g for 10 min at 4°C, washed three'times with sterile absolute ethanol, and dissolved in sterile distilled water. The bulk product, which was soluble but slightly opalescent, was stored at -600C.
Lot BP2-PA-3 was prepared from 30 liters of culture essentially as described for the partially purified capsular polysaccharide component of lot BP2-WZ-2. Differences in the procedure were that (a) the precipitate obtained by addition of hexadecyltrimethylammonium bromide was washed twice with water before extraction with 1 M CaCl2, and that (b) the reprecipitated polysaccharide-protein complex was washed four times with ethanol, dissolved in distilled water, and lyophilized. The lyophilized material was dissolved in distilled water at 1 mg/ml and prefiltered through 1. (6) .
The molecular size ofthe vaccines was determined by chromatography on a 2.5 x 37-cm column of Sepharose CL-4B (Pharmacia Fine Chemicals) equilibrated with either 0.05 M Tris-Cl, 0.15 M NaCl, pH 7.4, Tris-buffered saline (TS), or 1% DOC, 0.05 M glycine, 0.005 M EDTA, pH 8.8. In the latter instance, the sample was first equilibrated in 3% DOC, 0.01 M EDTA, and 0.05 M glycine, pH 8.8. Determination of the partition coefficient, Kd, was done as described by Wong et al. (25) .
CsCl equilibrium density gradient analysis of the vaccines was performed with an initial one-step gradient (26) (27) . The concentration of acrylamide was 12.5% wt/vol in the resolving gel and 3.6% in the stacking gel. N,N'-diallyltartardiamide was used as the cross-linker at concentrations of 0.54 and 0.156% wt/vol, respectively. The electrode buffer concentration was doubled, and both the stacking and resolving gels contained 0.5 M urea. Fixing and staining of the gel slabs was performed as described by Weber and Osborne (28) . Densitometer tracings of stained slabs were made with a Zeineh Soft Laser Scanning Densitometer (Biomed Instruments, Inc., Chicago, Ill.).
Serological assays. Radioactive bactericidal assays were done by the method of Kasper and Wyle (29) with serum from 1-mo-old rabbits as a source of complement. The end point was taken as the highest dilution giving 50% of the maximum net release of radioactivity. Freezing and thawing of sera were kept to a minimum, and prevaccination sera, together with one or more postvaccination sera from all volunteers, were tested against a given strain in the same assay. Based on replicate assays of a single serum, estimated 95% confidence levels for titers obtained in a single assay were plus or minus 14% of the number of serial two-fold dilutions.
For bactericidal inhibitions, a constant dilution ofantiserum was preincubated for 1 h at 36°C with serial dilutions of antigen. The highest dilution of antibody that could produce maximum release of radioactivity was used in each case and the amount of antigen required to produce 50% inhibition was determined from a plot of percentage of 14C release vs. log (inhibitor concentration).
Absorption of antisera with bacterial cells was performed as described (20) , and absorption with alum-adsorbed LPS or capsular polysaccharide was done as described by Gold- schneider et al. (30) .
The SPRIA was performed as described (31) . Calculation of micrograms antibody protein per milliliter was performed by reference to a calibrated serum having a known amount of specific antibody per milliliter as determined by quantitative precipitin assays. Calibration of the assay for determination of IgG, IgA, and IgM antibodies was done by reference to standard curves constructed by allowing serial dilutions of samples containing known amounts of IgA, IgG, or IgM to be bound by the corresponding heavy chain-specific goat antihuman immunoglobulin adsorbed to the surface of a plate. The assay was then completed as described (31) with the homologous heavy chain-specific 1251-goat anti-human immunoglobulin to detect the amount ofhuman antibody bound.
SPRIA inhibition assays were performed as described (20) by using an antigen concentration of 100 ,ug protein/ml except that in cases where a minimum concentration resulting in 50% inhibition (MIC50) is given, serial twofold dilutions of the antigen were tested and the concentration required to give 50% inhibition was determined. The OMC, LPS antigens, and purified meningococcal and E. coli KI capsular polysaccharides were prepared as described (6, 8) .
The percentage of anti-99M antibodies as detected by SPRIA that were specific for the type 2 protein was estimated by inhibition with OMC from strains of several different serotypes. The percentage of inhibition by an excess of OMC (100 ,ug protein/ml) from the homologous strain, three type Safety and immunogenicity in animals. The degree of immunogenicity of the vaccines in rabbits was determined by giving two 120-,g (dry weight) doses either subcutaneously or intravenously 3 wk apart. Sera were obtained at 0, 1, and 4 wk.
Toxicity tests in mice and general safety tests in mice and guinea pigs were performed as described in sections 620.5 and 610.11, respectively, ofthe Code of Federal Regulations.3 Pyrogenicity of the vaccines in rabbits was investigated by testing serial dilutions to determine the largest nonpyrogenic dose. Tests were performed as described in section 610. 13 (Table I) . Protein plus silaic acid accounted for about 95% of the dry weight of lot BP2-WZ-2 and 87% of lot BP2-PA-3. Nucleic acid was _1%, and although trace amounts of LPS were present, 2-keto-3-deoxyoctonate could not be directly determined by colorimetric assay due to strong interference by sialic acid. Rabbit pyrogen tests indicated that the level of LPS in lot BP2-PA-3 was severalfold higher than in BP2-WZ-2 (see below).
The vaccines were analyzed by SDS-PAGE to determine the number of polypeptides present and the relative amount and molecular weight of each. Densitometer tracings of the stained slab are shown in Fig. 1 . The two vaccine lots exhibited the same five major bands, which are also typical of the OMC from strain 99M, but differed in the relative proportions of each. Band 1 is a high molecular weight protein with an estimated molecular weight of > 150,000 daltons. Band 3, with a molecular weight of about 43,000 daltons, is the "principal" outer membrane protein and corresponds to the 41,000-dalton protein that has been reported to carry the protein serotype 2 determinants (36). The discrepancy in molecular weight is likely a reflection of the different gel systems used. This band represents 26% of the protein in lot BP2-WZ-2 and 14% of the protein in lot BP2-PA-3. Bands 4 and 5, which are actually three to four poorly resolved bands, comprise about half of the total protein in these lots.
Physical properties. The extent and nature of the interaction between the protein and polysaccharide components of the vaccine were investigated in two ways. Gel filtration ofthe vaccines on Sepharose CL-4B in the presence or absence of 1% DOC suggested there was considerable binding between the two components. In the absence of DOC ( Fig. 2A) , most of the polysaccharide and protein coeluted at the void volume followed by a second smaller peak at a Kd of about 0.35. In the presence of DOC, however, the polysaccharide appeared smaller in size, eluting as a single peak with a Kd of 0.34, and the protein eluted in several peaks independently of the polysaccharide (Fig. 2B) . More convincing evidence of protein-polysaccharide binding was obtained by isopycnic density gradient centrifugation of the vaccines in CsCl. The profile obtained with lot BP2-WZ-2 is shown in Fig. 3A and compared with purified group B polysaccharide containing only about 1% protein in Fig. 3B . The B polysaccharide alone produced a single band at a density of 1.66 g/cm3, whereas the B polysaccharide in the vaccine was found at all densities between 1.66 g/cm3 and the top ofthe gradient (1.47 g/cm3). Similarly, the protein in the vaccine was found not only at the top of the gradient, where pure protein would be expected to band, but at all densities down through the gradient to the point where the pure polysaccharide banded. The ultraviolet absorbance at the bottom ofthe gradients was probably the result ofcontaminating nucleic acid. These results demonstrated binding of the protein to the polysaccharide in widely variable proportions. To determine whether any particular protein was binding to the polysaccharide preferentially, the fractions were divided into three pools as indicated in Fig. 3A , and the material in each pool subjected to SDS-PAGE (Fig. 4) . Exactly the same proteins were found in all three pools, although only very little protein was present in pool 1. Fig. 4 ). 840 Zollinger, Mandrell, Griffiss, Altieri, and Berman charide. Group The antigenic activity and specificity of the protein antigens in the vaccines were investigated by measuring their capcity to inhibit serotype-specific antibodies in both bactericidal and SPRIA test systems (Table IV) . In both systems <10% inhibition was obtained with 99M LPS, group B polysaccharide, or OMC from the nontype P2 strains 321(C:P6), M981(B:P14), and M1080(B:P11) at 100 ,ug protein/ml. On the other hand, OMC from the three serotype P2 strains, 1381(C:P2), M1011(B:P2,6,10), or M986(B:P2,6), gave at least 80% inhibition at 100.ug/ml in the SPRIA test system; and OMC from strains 138I(C:P2) and M986-(B:P2,6), but not M1011 (B:P2,6, 10), gave >80% inhibition in the bactericidal test system. Thus, the SPRIA test system appeared to be serotype P2 specific and the bactericidal test system was specific for a protein present on some but not all serotype P2 strains (serotype 2 associated). Clear differences in the capacity of these test systems to distinguish among the antigens tested are evident. The protein determinant against which the human, naturally acquired bacterici- Safety and toxicity in animals. The vaccines were tested for safety and toxicity in mice at a level of 115 ,ug (BP2-WZ-2) or 150 ,ug (BP2-PA-3) dry wt, and for safety in guinea pigs at a 10-fold higher dose. All animals survived, appeared healthy, and showed a weight gain at the end of the 3-and(or) 7-d observation period.
In standard rabbit pyrogenicity tests, lot BP2-WZ-2 was found to be nonpyrogenic at a dose of 1 ug (dry weight) per kilogram rabbit weight, but a mean temperature rise of 0.75°C was observed at a level of 2 jig/kg. Lot BP2-PA-3 was nonpyrogenic at 0.37 ,ug/kg but produced a mean temperature rise of 1°C at 0.5 jig/kg.
Preliminary safety and immunogenicity tests in volunteers. Each vaccine lot was tested for safety and immunogenicity in four volunteers as described in Methods. No immediate reactions to the skin tests were observed. After 2-4 h, however, mild local reactions to the skin tests and the vaccinations developed in all volunteers. These reactions were maximum at 24 h, and had disappeared by 72 h. They consisted of erythema frequently accompanied by slight induration and tenderness. After the first injection, the mean diameter of reactions at the skin test site at 24 h was 2.8 cm for lot BP2-WZ-2 and 3.5 cm for lot BP2-PA-3. The mean diameter of the reactions at the vaccination site was 4.8 cm for lot BP2-WZ-2 and 7.5 for lot BP2-PA-3. Detectable induration was present in all cases. After the second injection at 5 wk the reactions at the skin test site at 24 h had a mean diameter of 3 cm for lot BP2-WZ-2 and 2.8 cm for lot BP2-PA-3, but only four of eight had detectable induration. The mean diameter of the reactions at the vaccination site was 3.8 cm for lot BP2-WZ-2 and 7.0 cm for lot BP2-PA-3, and only three of eight had detectable induration. No systemic reactions were observed.
All throat cultures were negative for N. meningitidis throughout the study. Stool samples from two volunteers (Nos. 6 and 7), however, were consistently found to contain E. coli KI organisms.
The bactericidal antibody response of the volunteers to the first dose of vaccine was determined by testing the pre-and 2-wk postvaccination sera against several different meningococcal strains (Table V) . Six of the eight volunteers developed fourfold or greater increases in bactericidal antibody to the vaccine strain (99M). The two who did not respond had high preexisting titers (1:128 and 1:256). The mean rise to lot BP2-WZ-2 was 32-fold and to lot BP2-PA-3 was about 8-fold. Bactericidal antibody specific for the B polysaccharide component of the vaccine was determined by testing the capacity of the sera to kill three different group B strains which lacked the serotype P2 antigen (Table V) . The titers against these strains were nearly as high as against the vaccine strain, suggesting that much of the bactericidal antibody was directed against the group B polysaccharide. This was confirmed by absorption of the sera with purified E. coli Kl capsular polysaccharide. This absorption removed all bactericidal activity against these nontype P2 strains in both pre-and postvaccination sera.
Bactericidal antibodies against the protein part of the vaccine were assayed by testing the sera against the group C type P2 strain 1381 after absorbing with the group C type P3,4 strain 118V, and also testing the sera against the vaccine strain after absorbing with the group B type P14 strain M981. The resultant titers in the two assays were similar except for volunteer 2 who had antibodies remaining against the vaccine strain but not against 1381 (Table V) . Seven of the 842 Zollinger, Mandrell, Griffiss, Altieri, and Berman eight volunteers had a detectable rise in titer against one of the two strains. Further absorption of these sera with 99M LPS failed to remove this antibody. This strongly suggested that seven of the volunteers had developed type-specific bactericidal antibody against the protein antigens. The persistence of the bactericidal antibodies induced by the vaccine and the effect of a second dose of vaccine given at 5 wk is summarized in Table VI . In contrast to the strong antibody response of rabbits to a second dose of vaccine, only a slight booster effect was observed in the volunteers. The geometric mean group B antibody titers (vs. strain 6155), which had decreased from the 2-wk level, were partially restored but did not reach the original 2-wk level. At 14 wk the titers had again fallen off but remained approximately sixfold above the prevaccination level. Bactericidal antibodies to the protein antigens (vs. strain 1381) also decreased and at 14 wk had completely disappeared in those who received lot BP2-PA-3.
Antibodies to the outer membrane proteins were also assayed by SPRIA by using OMC from strain 99M as antigen (Table VII) . Because the OMC contains LPS antigens as well as outer membrane proteins, the sera were also tested against purified 99M LPS as a control. The difference between the amount of antibody binding to the OMC and that binding to the LPS was assumed to represent antibody binding to outer membrane proteins. In the postvaccination sera, over 95% of the antibody that bound to the OMC appeared to be directed against the proteins. All eight volunteers responded to the first dose of vaccine with increased levels ofantibody to the outer membrane proteins. The range of the rises was 2-to 30-fold, and the mean rise for both vaccine lots was about 8-fold. Little if any increase resulted from the second dose. The antibody levels dropped by -50% through the first 14 wk. A slight increase in antibodies to LPS was seen with lot BP2-PA-3.
The specificity of the antiprotein antibodies measured by SPRIA was determined as described in Meth- ods. A mean of 63% of the antiprotein antibodies induced by lot BP2-WZ-2 and 47% of those induced by lot BP2-PA-3 were specific for the type 2 protein (Table VIII) .
Increases in antibody to the group B polysaccharide were confirmed by passive HA assays. Lot BP2-WZ-2 induced a mean eightfold rise in HA antibody to the B polysaccharide which decreased to fourfold after 14 wk (Table IX) . Similarly, lot BP2-PA-3 induced a mean fivefold rise which decreased to threefold after 14 wk. Six ofthe eight volunteers had a 4-fold or greater rise, and one volunteer (No. 4) had a 64-fold rise at 2 wk. The immunoglobulin class of the anti-group B polysaccharide antibodies was determined by fractionation of a pool of the 10-wk postvaccination sera from volunteers 2 and 4. The IgM, IgG, and IgA fractions, which exhibited cross-contamination of <1% based on assays with low level radial immunodiffusion plates, were tested for antibody to the group B polysaccharide by bactericidal and HA assays (Table X) . Bactericidal and HA antibodies appeared to be mostly of the IgM class. Group B-specific IgG antibodies were present at much lower titer and group Bspecific IgA antibodies were not detected, although IgA antibodies were detected by HA (equivalent titer 1:32) after similar fractionation of 5-wk sera from the same individuals. Preliminary tests with a sensitive radioactive antigen binding assay have also failed to demonstrate a good IgG response to the group B polysaccharide.
That the antibody response to the protein component of the vaccine involved antibodies of all three major immunoglobulin classes was demonstrated by the SPRIA using heavy chain-specific second antibody (Table XI) . The pre-and postimmunization sera from two volunteers who received lot BP2-WZ-2 were assayed. In both cases IgG antibodies showed the largest increase, and the IgA antibodies appeared to be the least persistent.
DISCUSSION
Immunization of a small number of volunteers with a noncovalent complex of meningococcal group B polysaccharide and type 2 outer membrane proteins has demonstrated that both components ofthe complex are immunogenic in man when presented in this form. The complex described here, which involved noncovalent hydrophobic binding between two surface antigens, may be very similar to the natural association of these antigens on the surface of the viable organism. The (19) . Now that the immunogenicity of this type ofprotein-polysaccharide complex has been demonstrated in man, base-line immunogenicity and safety data can be obtained which will provide a reference point for future studies directed toward standardization of the vaccine and optimizing its composition with respect to the protein species present.
The group B-specific antibodies might, in theory, be expected to protect against all group B strains, but there is some evidence that suggests that the group B-specific antibodies may not be of sufficiently high quality to provide uniform, long-lasting protection against all group B strains (7) . In this case, serotype P2-specific antibodies may provide important backup protection against at least type P2 strains which have figured prominently in recent group B and group C epidemics (2, 12, 13) . Type P2-specific antibodies Vaccine was administered at 0 and 5 wk. gangliosides (39) . This conclusion is supported by our unpublished observation that several human sera with group B-specific bactericidal antibody titers in excess of 1:1000 failed to effect complement-mediated lysis of GTl-sensitized liposomes.5 Because animal models have thus far been relatively useless for predicting human antibody responses to meningococcal antigens, several in vitro assays were developed to monitor the antigenic activity and specificity of the vaccine components. These assays involved quantitation of the capacity of an antigen preparation to inhibit the reaction of human antibodies or rabbit antibodies induced by the native form of the antigen with the native antigen. In the case of the protein, the SPRIA test system (Table IV) was able to clearly distinguish between an earlier vaccine lot that was exposed to high pH during its preparation and was poorly immunogenic in man and the present vaccines in which the protein component produced a much stronger antibody response in man. Such assays may, therefore, be useful for monitoring the antigenic activity of the protein antigens in the vaccine.
The limited data obtained in this initial study suggest that the vaccine is safe. Adverse side effects were limited to local reactions which, although stronger than those normally seen with purified meningococcal polysaccharide vaccines (5, 40, 41) , were relatively mild and disappeared in 2 or 3 d. Whether the reactogenicity is directly related to the level of contaminants, such as endotoxin, or is an intrinsic property of the proteinpolysaccharide complex is presently under investigation.
Vaccine lots BP2-WZ-2 and BP2-PA-3 differed mainly in the method of their preparation and in the relative proportions of the separate components present. The principal reason for testing lot BP2-PA-3, which had a higher level of contaminating LPS, was that the protein in that lot appeared to have greater antigenic activity than the protein in lot BP2-WZ-2, presumably because it had not been exposed to DOC. We had thus anticipated that lot BP2-PA-3 might produce an antibody response to the protein, whereas lot BP2-WZ-2 might not. Although only a few volunteers were vaccinated in this initial phase of testing, it was clear that the two lots were roughly equivalent in their capacity to induce an antibody response to the proteins as determined by SPRIA. Lot BP2-PA-3, however, appeared to produce a higher mean type-specific bactericidal antibody response, but the numbers are too small to be certain.
To determine whether the level and quality of the antibody response to the vaccines is sufficient to provide effective, long-lasting protection will require efficacy trials in a suitable population experiencing group B meningococcal disease. An evaluation of the nature 5 Zollinger, W. D., and C. Alving. Unpublished observations. of the antibody response obtained in these few initial volunteers, however, has revealed somne significant differences between the human antibody response to the group B polysaccharide and that to the group A and group C polysaccharides. For example, Gotschlich et al. (14) found that although all three classes of antibodies were induced by the meningococcal group A and C vaccines, the bactericidal antibodies were predominantly of the IgG class. This is in sharp contrast to our finding that the bactericidal antibodies induced by the present group B vaccine were nearly all of the IgM class. The IgM character of these antibodies may explain the observed decline of the antibody titers over a 3-mo period.
Although two of the volunteers had little or no antibody response to the group B polysaccharide, they were the two with the highest prevaccination titers of bactericidal antibody. Those volunteers with the lowest prevaccination titers, and therefore most in need of protection, were among the strongest responders. As protection has been correlated with the presence of serum bactericidal antibodies (15, 16) , it is reasonable to expect that the bactericidal antibodies induced by these vaccines will be protective, and although serum bactericidal antibodies decreased considerably over a period of 14 wk, mean titers remained above the prevaccination levels. In addition, because military recruits are at greatest risk during their initial 7 wk of basic training, even shorter protection would be ofsignificant value in this setting. Noncovalent complexes of group B polysaccharide and outer membrane protein thus appear to have considerable potential as a vaccine against group B meningococcal disease and warrant further development and testing in larger numbers of volunteers.
